Business Context and Reporting Period
This Form 8-K Current Report was filed by Profound Medical Corp. (Nasdaq: PROF) on September 3, 2026, covering events occurring on September 1, 2026. The filing primarily addresses a significant change in executive leadership and the associated compensatory arrangements.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive appointments and compensation terms.
Material Changes
- Executive Appointment: Richard R. Fabian was appointed President, effective September 1, 2026.
- Role Transition: Mathieu Burtnyk, PhD, transitioned from President to the newly created role of Chief Technology Officer, effective September 1, 2026.
- Compensation Structure: Mr. Fabian's employment agreement includes an annualized base salary of $550,000 and an annual discretionary bonus of up to 100% of base salary.
- Equity Grants: Mr. Fabian received 200,000 restricted share units (vesting over three years) and options to purchase 475,000 common shares (vesting over four years).
- Relocation Benefits: The Company will lease a residence in Toronto for Mr. Fabian for the initial 12 months and provide a monthly car allowance of $1,000.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or management commentary regarding future business performance. No specific risks or contingencies related to the appointment were disclosed beyond standard regulatory language. The full text of the Employment Agreement is referenced as an exhibit to be filed in the subsequent Form 10-Q.
Investor Verification Checklist
- Verify the full terms of the Employment Agreement in the upcoming Form 10-Q filing.
- Confirm the vesting schedules and performance conditions for the 200,000 RSUs and 475,000 stock options granted to Mr. Fabian.
- Review the press release (Exhibit 99.1) for additional strategic context regarding the leadership transition.
- Monitor future filings for any impact of the new executive structure on operational strategy or financial results.